Average one-year price target for Akari Therapeutics (NasdaqCM: AKTX) was revised to $108.12 from $2.70, a 3,900% increase versus the prior estimate dated March 25, 2026. Such a dramatic upward revision is likely to materially re-rate sentiment and could drive significant upside and trading activity in the stock driven by analyst-driven flows.
Average one-year price target for Akari Therapeutics (NasdaqCM: AKTX) was revised to $108.12 from $2.70, a 3,900% increase versus the prior estimate dated March 25, 2026. Such a dramatic upward revision is likely to materially re-rate sentiment and could drive significant upside and trading activity in the stock driven by analyst-driven flows.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
